http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical t
-
Guardant Health Named to TIME100 Most Influential Companies
-
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
-
Guardant Health (GH): FDA Advisory Committee Panel Strongly Recommends Approval of Shield Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
-
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
-
Guardant Health (GH) Reports FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
-
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health (GH) Receives EU IVDR Certification for Guardant360 CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
-
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
-
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
-
Guardant Health (GH) Announces FDA Advisory Panel Review of Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
-
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
-
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
-
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
-
Guardant Health (GH) Announces Publication of ECLIPSE Study Data
-
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
-
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
-
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
-
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
-
Guardant Health (GH) Announces Preliminary Fourth Quarter and Full Year 2023 Results
-
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
-
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
-
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
-
Guardant Health (GH) Announces 3.39M Share Offering at $26.77/sh
-
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
-
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Guardant Health (GH) Announces Tentative Date of FDA Advisory Panel Review of Shield Blood Test
-
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
-
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
-
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guardant Health (GH) to Appeal Federal District Court Verdict
-
Guardant Health to Appeal Federal District Court Verdict
-
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
-
Guardant Health to Participate in Upcoming November Investor Conferences
-
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
-
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
-
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
-
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
-
Guardant Health (GH) Receives Regulatory Approval in Japan for Guardant360 CDx as Companion Diagnostic to ENHERTU
-
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
-
Guardant Health (GH) Provides Update on COBRA Study, Restates Confidence in MRD Test
-
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
